NCT06946290 Intertransverse Process Block to Improve Quality of Recovery and Pain Management in Adult Cardiac Surgical Patients
| NCT ID | NCT06946290 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chinese University of Hong Kong |
| Condition | Chronic Postsurgical Pain |
| Study Type | INTERVENTIONAL |
| Enrollment | 96 participants |
| Start Date | 2026-01-02 |
| Primary Completion | 2027-01-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 96 participants in total. It began in 2026-01-02 with a primary completion date of 2027-01-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to evaluate the efficacy of intertransverse process block (ITPB) in improving quality of recovery and potentially preventing chronic postsurgical pain (CPSP) in adult patients undergoing elective cardiac surgery (e.g., coronary artery bypass graft \[CABG\], valve repair/replacement, or combined CABG/valve procedures). The main questions it aims to answer are: 1. To investigate the quality of recovery after cardiac surgery, and its analgesic efficacy in the immediate postoperative period 2. To investigate the efficacy of intertransverse process block (ITPB) on CPSP after cardiac surgery by determining the incidence of CPSP at 3 month, defined as persistent pain that was not present before surgery or that had different characteristics, and other possible causes of pain are excluded. 3. To investigate the efficacy of ITPB on the incidence of CPSP at 6 month, 12 month, and the pain interference (sensory and affective components, physical activities) at 3 month, 6 month and 12 month after surgery
Eligibility Criteria
Inclusion Criteria: * adult patients aged 18 or older * undergoing elective CABG, valve repair/replacement, or combined CABG/valve procedure via sternotomy Exclusion Criteria: * Emergency surgery * redo surgery * history of chronic pain or being on chronic opioids/sedatives * renal failure with an estimated glomerular filtration rate ≤30 ml/min (calculated by Cockcroft-Gault formula) * re-operation within 24 hours after surgery * intraoperative use of remifentanil * inability to provide informed consent.
Contact & Investigator
Henry Wong
PRINCIPAL INVESTIGATOR
Hospital Authority
Frequently Asked Questions
Who can join the NCT06946290 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Postsurgical Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06946290 currently recruiting?
Yes, NCT06946290 is actively recruiting participants. Contact the research team at yhosum928@gmail.com for enrollment information.
Where is the NCT06946290 trial being conducted?
This trial is being conducted at Hong Kong, Hong Kong.
Who is sponsoring the NCT06946290 clinical trial?
NCT06946290 is sponsored by Chinese University of Hong Kong. The principal investigator is Henry Wong at Hospital Authority. The trial plans to enroll 96 participants.